Expedited Programs for Serious Conditions | Drugs and Biologics
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
May 30, 2014
December 14, 2023
d49c172d-43db-4e76-a0fd-1f51de9ecff3
Related Documents
Dear Health Care Provider Letters: Improving Communication of Important Safety Information
Guidance DocumentJanuary 2, 2014Center for Drug Evaluation and Research
CMC Postapproval Manufacturing Changes To Be Documented in Annual Reports
Guidance DocumentMarch 5, 2014Center for Drug Evaluation and Research
User Fee Waivers, Reductions, and Refunds for Drug and Biological Products
Guidance DocumentSeptember 27, 2011Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Stay ahead of FDA enforcement
New KeyPedia insights, webinars, and regulatory analysis — straight to your inbox. Unsubscribe anytime.